NCT00881569View on ClinicalTrials.gov

Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

September 30, 2011

Conditions
Advanced Cancer
Interventions
DRUG

CS-7017

CS-7017 administered orally, twice daily continuously for 6 weeks

Trial Locations (1)

Unknown

Washington D.C.

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY